Our Anti-DSCC1 polyclonal used in lung cancer research
DSCC1 is a novel therapeutic target to treat lung adenocarcinoma.
University School of Medicine, Hangzhou, 310006 China
Lung cancer is a leading cause of cancer-related deaths, and the most common type is lung adenocarcinoma (LUAD).
LUAD is frequently diagnosed in people who never smoked, patients are always diagnosed at advanced inoperable stages, and the prognosis is ultimately poor.
Thus, there is an urgent need for the development of novel targeted therapeutics to suppress LUAD progression.
In this study, the authors show that the expression of DNA replication and sister chromatid cohesion 1 (DSCC1) was higher in LUAD samples than in normal tissues, and the overexpression of DSCC1 or its coexpressed genes was highly correlated with poor outcomes of LUAD patients, highlighting DSCC1 might be involved in LUAD progression.
Using our anti-DSCC1 Triple A polyclonal (HPA024401) the study reveals that DSCC1 is a novel therapeutic target to treat LUAD and a biomarker for predicting the efficiency of PD-1/PD-L1 blockade treatment.
Read the full article here: Lin X, Liu YH, Zhang HQ, Wu LW, Li Q, Deng J, Zhang Q, Yang Y, Zhang C, Li YL, Hu J. DSCC1 interacts with HSP90AB1 and promotes the progression of lung adenocarcinoma via regulating ER stress. Cancer Cell Int. 2023 Sep 23;23(1):208.
Learn more about our TripleA polyclonals
🌎 Our antibodies are used worldwide 🌎